All Sections

Site Selection

Facility Planning

Workforce Development

Business+Place

AD Editorial Board

Alan Reeves

Senior Managing Director, Global Strategy, Newmark
Alexandra Segers

General Manager, Tochi Advisors
Amy Gerber

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Bradley Migdal

Executive Managing Director, Americas Strategic Consulting, Cushman & Wakefield
Brian Corde

Managing Partner, Atlas Insight
Brian Gallagher

Vice President, Corporate Strategy and Development, PPC Partners, Inc.
Chris Chmura, Ph.D.

CEO & Founder, Chmura Economics
Chris Schwinden

Partner, Site Selection Group
Chris Volney

Managing Director, Americas Consulting, CBRE
Courtland Robinson

Director of Business Development, Brasfield & Gorrie
Courtney Dunbar

Site Selection & Economic Development Leader, Burns & McDonnell
David Hickey

Managing Director, Hickey & Associates
Dennis Cuneo

Former Senior Vice President, Toyota Motor North America; Owner , DC Strategic Advisors
Dianne Jones

Managing Director, Business and Economic Incentives, JLL
Eric Stavriotis

Vice Chairman, CBRE
Joe Dunlap

Chief Supply Chain Officer, Legacy Investing
Lauren Berry

Director, Location Analysis and Incentives, Maxis Advisors
Marc Beauchamp

President, SCI Global
Matthew Powers

Site Selection Lead, REDI Site Selection
Scott J. Ziance

Partner and Economic Incentives Practice Leader, Vorys, Sater, Seymour and Pease LLP
Scott Kupperman

Founder, Kupperman Location Solutions
Stephen Gray

President & CEO, Gray Construction

Samsung Biologics Plans Rockville, Maryland, Manufacturing Operations

Area Development News Desk

12/31/2025

South Korea-based biotechnology company Samsung Biologics plans to establish manufacturing operations in Rockville, Maryland. The $280 million project is expected to retain 500 jobs in Montgomery County.

The investment includes the acquisition and upgrade of the GSK campus which will feature expanded drug substance manufacturing capacity and handle both clinical and commercial production.

“This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics,” said Samsung Biologics Chief Executive Officer and President John Rim. “This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact.”

Samsung Biologics is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for biologics, from late-stage discovery to large-scale commercial manufacturing, including cell line development, process development, analytical testing, and aseptic fill/finish.

“With this new facility, Samsung Biologics will be at the heart of one of the top U.S. life sciences clusters which is home to a critical mass of private companies, world-class universities, and myriad federal facilities,” noted Maryland Department of Commerce Secretary Harry Coker, Jr. “We look forward to working with Samsung as they transition to their new home in Maryland and helping them grow and expand here.”

Project Announcements